ReviewInternational journal of ophthalmology2019
Differentiation of retinal ganglion cells from induced pluripotent stem cells: a review.
Review in International journal of ophthalmology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 28 citations in OpenAlex.
- Stem Cell Therapy: Past, Present, and Future Aspects.Biomedicines · 2026Review
- Human pluripotent stem cell-derived retinal ganglion cells: advances in differentiation and translational applications.Molecular medicine (Cambridge, Mass.) · 2025Review
- Magnetically guided neurite outgrowth modulated by PIEZO1 in hiPSC-derived retinal ganglion cells.Materials today. Bio · 2025Article
- Rekindling Vision: Innovative Strategies for Treating Retinal Degeneration.International journal of molecular sciences · 2025Review
- Generation of Retinal Ganglion Cells from Reprogrammed Keratocytes of Non-Glaucoma and Glaucoma Donors.Current protocols · 2025Article
- Review
- Retinal Ganglion Cell Replacement in Glaucoma Therapy: A Narrative Review.Journal of clinical medicine · 2024Review
- Cell replacement with stem cell-derived retinal ganglion cells from different protocols.Neural regeneration research · 2024Review
- Therapeutic strategies for glaucoma and optic neuropathies.Molecular aspects of medicine · 2023Review
- Human retinal ganglion cell neurons generated by synchronous BMP inhibition and transcription factor mediated reprogramming.NPJ Regenerative medicine · 2023Article
- The efficient induction of human retinal ganglion-like cells provides a platform for studying optic neuropathies.Cellular and molecular life sciences : CMLS · 2023Article
- Abnormal morphology and function in retinal ganglion cells derived from patients-specific iPSCs generated from individuals with Leber's hereditary optic neuropathy.Human molecular genetics · 2023Article
- A Microfluidic Eye Facsimile System to Examine the Migration of Stem-like Cells.Micromachines · 2022Article
- In vitro disease modeling of oculocutaneous albinism type 1 and 2 using human induced pluripotent stem cell-derived retinal pigment epithelium.Stem cell reports · 2022Article
- Utilization of Modified Induced Pluripotent Stem Cells as the Advance Therapy of Glaucoma: A Systematic Review.Clinical ophthalmology (Auckland, N.Z.) · 2022Review
- Human neural organoids: Models for developmental neurobiology and disease.Developmental biology · 2021Review
- Quantitative Approaches to Study Retinal Neurogenesis.Biomedicines · 2021Review
- Retinal Ganglion Cell Transplantation: Approaches for Overcoming Challenges to Functional Integration.Cells · 2021Review
- Cell transplantation to replace retinal ganglion cells faces challenges - the Switchboard Dilemma.Neural regeneration research · 2021Review
- The internal limiting membrane: Roles in retinal development and implications for emerging ocular therapies.Experimental eye research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glaucoma is a common optic neuropathy that is characterized by the progressive degeneration of axons and the loss of retinal ganglion cells (RGCs). Glaucoma is one of the leading causes of irreversible blindness worldwide. Current glaucoma treatments only slow the progression of RGCs loss. Induced pluripotent stem cells (iPSCs) are capable of differentiating into all three germ layer cell lineages. iPSCs can be patient-specific, making iPSC-derived RGCs a promising candidate for cell replacement. In this review, we focus on discussing the detailed approaches used to differentiate iPSCs into RGCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.